We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
Abrysvo Pfizer Australia Pty Ltd
Product name
Abrysvo
Sponsor
Accepted date
Apr-2026
Active ingredients
recombinant respiratory syncytial virus pre-fusion F protein, water for injections
Summary of proposed indication
ABRYSVO is a respiratory syncitial virus (RSV) vaccine that is proposed for the vaccination of:
-pregnant women at 24 to 36 weeks of pregnancy, to immunise against RSV-related lower respiratory tract disease in infants from birth to 6 months of age.
-people aged 18 years and older, to immunise against RSV-related lower respiratory tract disease. This vaccine should be used according to official health recommendations.
-pregnant women at 24 to 36 weeks of pregnancy, to immunise against RSV-related lower respiratory tract disease in infants from birth to 6 months of age.
-people aged 18 years and older, to immunise against RSV-related lower respiratory tract disease. This vaccine should be used according to official health recommendations.
Application type
C (new indication)
Publication date
Apr-2026